Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

51.38 -0.34 (-0.67%)
Streaming Delayed Price Updated: 2:40 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 846,337
Open 51.52
Bid (Size) 51.38 (7)
Ask (Size) 51.39 (7)
Prev. Close 51.73
Today's Range 51.26 - 51.62
52wk Range 45.13 - 58.97
Shares Outstanding 1,250,690,553
Dividend Yield 3.70%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:SNY stands out as a stock that provides good value for the fundamentals it showcases.
SANOFI-ADR (NASDAQ:SNY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+2.77%
+2.77%
1 Month
-6.32%
-6.32%
3 Month
-1.39%
-1.39%
6 Month
+5.54%
+5.54%
1 Year
+12.24%
+12.24%

More News

Read More
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Via Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Via Benzinga
Exposures Product Safety
Sanofi's Earnings Outlook
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
Why Sanofi Stock Flew Higher on Friday
Via The Motley Fool
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Via Benzinga
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
Via Investor's Business Daily
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Via Benzinga
Markets Mixed Again; DECK, SKX Beat After The Bell
Via Talk Markets
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Via Benzinga
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?
Via The Motley Fool
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
Via Benzinga
France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block
Via Benzinga
Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R
Via Benzinga
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Via Benzinga
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
Via Benzinga
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Via Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.